He describes his work in these diseases and how Oxford-Harrington has provided funding and advice that has been valuable beyond the feedback he typically receives in an academic setting.

He highlights the centre's Scholars program, which researchers anywhere can apply for and funds ten new drug development programs each year. Plus the centre's accelerator program and plans for a rare disease investment fund. He also discusses how regulatory changes at places like MHRA can help the rare disease community.

MassBio President & CEO Kendalle Burlin O'Connell moderates a discussion with Aurora Therapeutics CEO Ed Kaye and DaCapo Brainscience CEO Leslie Williams about being biotech leaders during this volatile time for the industry. They stress that a key to success is that everyone in the industry work together towards shared goals. Chapters Introductions - 1:19 Aurora Therapeutics - 5:34 DaCapo Brainscience - 9:37 Being patient centric - 11:00 The state of the industry - 19:04 Mas

He discusses upcoming readouts for IDEAYA Biosciences, Ocular Therapeutix (how it might affect EyePoint), and Palvella Therapeutics. Plus, his take on the recent Corvus atopic dermatitis data. Chapters IDEAYA Biosciences - 0:46 EyePoint / Ocular - 3:45 Palvella - 7:43 Corvus - 12:30

MLSC's President & CEO Kirk Taylor, MD describes the organization's mission, how biotech startups and others can search for and utilize equipment and facilities that might otherwise be out of reach, and his take on the current state of the ecosystem.

He discusses interest rates, generalist investor participation in the sector, and more.

She discusses Arrivent Biopharma, Oruka Therapeutics, Jade Biosciences, Zura Bio, and Pavella Therapeutics. Chapters General take on biotech - 0:52 Arrivent BioPharma - 4:20 Oruka Therapeutics - 6:46 Jade Biosciences - 9:18 Zura Bio - 12:07 Other catalysts / Pavella - 16:02

The biggest limiter, until now, has been data quality and integration across R&D systems. That is changing and the potential use cases are expanding rapidly.

He talks about Perceptive's investment philosophy, his take on the year ahead, areas he thinks are over and under hyped, and thoughts on China. Plus, the rationale for a few of his top holdings.

He discusses the theme of his annual letter that was published today, "Choosing Science," and why it is important that our country continues to invest in basic research. Plus, his take on the M&A environment in biotech.

He discusses Biohaven, Xenon, Biogen, and Sarepta.

His widely read report shows the data behind what venture deals got done last year, who are the venture investors that have been most active in deploying capital, the fundraising and IPO environment, and which technologies and indications are seeing the most investor interest. DOWNLOAD THE FREE REPORT #sponsored

He discusses BridgeBio, Cytokinetics, Vaxcyte, Biogen, and Arcus Biosciences Chapters BridgeBio - 1:08 Cytokinetics - 12:14 Vaxcyte - 17:40 Biogen - 23:43 Arcus Biosciences - 26:48

He discusses the recently approved Wegovy pill, and compares and contrasts it to other oral programs from Lilly, Structure, and Corbus. Plus, how is the amylin space looking compared to GLP-1s, and a preview of Viking's 2026. Chapters Wegovy in a pill - 1:04 Lilly’s pill orforglipron - 9:14 Structure’s pill aleniglipron - 13:13 Lilly’s retatrutide - 16:33 Amylins (Zealand and others) - 19:47 Corbus’ CB1 inverse agonist – 24:53 Viking - 28:02

We discuss the upcoming maintenance data, commercial prospects, Crohn's, and buyout prospects. Chapters Intro - 0:59 Maintenance - 3:54 Commercial prospects - 18:16 Crohn's - 21:43 Buyout prospects - 27:03 How did Wall Street analysts miss this? - 41:31

He mentions Terns, Corvus, Insmed, Corbus, Axsome, Neumora, Eyepoint, and Amylyx. Chapters His general take on biotech - 1:28 Terns - 7:25 Corvus - 12:49 Insmed - 16:26 Corbus - 20:44 Others with upcoming catalysts - 26:44

They describe an uptick in the mood of the industry as well as hiring. Plus, helping companies fulfill their goal to have an employee base that is back working in the office. Coverage brought to you by

Co-Founders Luke Evnin and Steven St. Peter describe the idea behind the firm, the value in partnering with philanthropies who know these diseases best, and why I&I is going through such a revolution currently.

CEO Iain Foulkes describes the impact Cancer Research Horizons has already made (14 marketed medicines), which has allowed more than £600M in royalty income to be reinvested in research. He describes the structure of the organization, a new startup fund, and some notable investments.

He describes getting through the last few years and how he thinks about 2026. Plus, comments on Xenon, Madrigal, and Alkermes. Brought to you by